MS910
MS910 is a CRBN-recruiting MEK1/2 PROTAC degrader, with a DC50 of 94 nM against MEK1 and 38 nM against MEK2 in SK-MEL-28 cells. MS910 induces the degradation of GSPT1, IKZF1/3 and ZFP91, thereby inhibiting the downstream ERK signaling pathway and cancer cell growth. MS910 is applicable to research related to colorectal cancer and melanoma.
(Pink: MEK1 and MEK2 ligand (HY-10254); Blue: Cereblon ligand (HY-W087383); Black: linker (HY-W022240)).
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 2756323-28-9
- Fòrmula: C41H48F3IN6O11
- Peso molecular:984.75
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas PROTACs
MoreVer todos los productos específicos de isoformas MEK
More
Actividad biológica
|
MEK1 94 nM (DC50, SK-MEL-28 cells) |
MEK2 38 nM (DC50, SK-MEL-28 cells) |
MEK1 118 nM (DC50, HT-29 cells) |
MEK2 55 nM (DC50, HT-29 cells) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-29 | GI50 |
0.3 μM
|
Antiproliferative activity against human HT-29 colorectal cancer cells assessed as reduction in cell viability incubated for 3 days by WST-8 assay.
Antiproliferative activity against human HT-29 colorectal cancer cells assessed as reduction in cell viability incubated for 3 days by WST-8 assay.
|
33284613 |
| SK-MEL-28 | GI50 |
780 nM
|
Antiproliferative activity against human SK-MEL-28 melanoma cells assessed as reduction in cell viability incubated for 3 days by WST-8 assay.
Antiproliferative activity against human SK-MEL-28 melanoma cells assessed as reduction in cell viability incubated for 3 days by WST-8 assay.
|
33284613 |
| HT-29 | DC50 |
118 nM
|
Degradation of MEK1 in human HT-29 colorectal cancer cells incubated for 24 h measured by Western blot assay.
Degradation of MEK1 in human HT-29 colorectal cancer cells incubated for 24 h measured by Western blot assay.
|
33284613 |
| HT-29 | DC50 |
55 nM
|
Degradation of MEK2 in human HT-29 colorectal cancer cells incubated for 24 h measured by Western blot assay.
Degradation of MEK2 in human HT-29 colorectal cancer cells incubated for 24 h measured by Western blot assay.
|
33284613 |
| SK-MEL-28 | DC50 |
94 nM
|
Degradation of MEK1 in human SK-MEL-28 melanoma cells incubated for 24 h measured by Western blot assay.
Degradation of MEK1 in human SK-MEL-28 melanoma cells incubated for 24 h measured by Western blot assay.
|
33284613 |
| SK-MEL-28 | DC50 |
38 nM
|
Degradation of MEK2 in human SK-MEL-28 melanoma cells incubated for 24 h measured by Western blot assay.
Degradation of MEK2 in human SK-MEL-28 melanoma cells incubated for 24 h measured by Western blot assay.
|
33284613 |
MS910 (compound 50) (3 days) inhibits the proliferation of SK-MEL-28 melanoma cells, with a GI50 of 780 nM[1].
MS910 (3 days) potently inhibits the proliferation of HT-29 colorectal cancer cells, with a GI50 of 0.3 μM[1].
MS910 (0-10 μM; 24 h) potently and selectively degrades MEK1 (DC50 = 118 nM) and MEK2 (DC50 = 55 nM) in HT-29 cells, while inhibiting the phosphorylation of downstream MEK and ERK[1].
MS910 (0-10 μM; 24 h) efficiently and selectively degrades MEK1 (DC50 = 94 nM) and MEK2 (DC50 = 38 nM) in SK-MEL-28 cells, while inhibiting the phosphorylation of downstream MEK and ERK[1].
MS910 (0.3 μM; 2-24 h) induces time-dependent degradation of MEK1 and MEK2 in HT-29 cells, with significant degradation observed at 4 h, maximal degradation achieved at 8-10 h, followed by inhibition of ERK phosphorylation[1].
MS910 (0.3 μM; 8 h) induces the degradation of MEK1/2 in HT-29 cells via the ubiquitin-proteasome system in a CRBN-dependent manner, a process that requires binding to MEK1/2[1].
MS910 (0-300 nM; 10 days) effectively inhibits colony formation of HT-29 colorectal cancer cells, and exhibits stronger activity than its non-degradative control[1].
Treatment of HT-29 and SK-MEL-28 cells with MS910 (0.1 nM-10 μM) for 24 h induces concentration-dependent degradation of MEK1 and MEK2 proteins[1].
MS910 (1 nM-100 μM) binds to MEK1 and MEK2 proteins in a concentration-dependent manner[1].
Treatment of HT-29 cells with MS910 (0.3 μM; 8 h) reduces the protein levels of MEK1 and MEK2[1].
MS910 (0.0001-10 μM; 24 h) induces concentration-dependent degradation of MEK1, MEK2, GSPT1, IKZF1 and IKZF3, but does not induce ZFP91 degradation, following 24-hour treatment of HT-29 cells[1].
MS910 (0.3 μM; 8 h) exhibits high selectivity for MEK1 and MEK2 in HT-29 cells[1].
MS910 (0.0001-10 μM; 24 h) does not degrade most CRBN neo-substrates (GSPT1, IKZF1, ZFP91) in HT-29 cells, but degrades IKZF3 at concentrations above 1 μM, and exhibits higher potency in degrading MEK1/2 than IKZF3[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HT-29 cells
-
Concentration:0.3 μM
-
Incubation Time:8 h
-
Result:Reduced MEK1 and MEK2 protein levels relative to DMSO control, confirming degradation of these proteins.
-
Cell Line:HT-29 cells
-
Concentration:0.0001, 0.0003, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 10 μM
-
Incubation Time:24 h
-
Result:Induced concentration-dependent degradation of MEK1 and MEK2 proteins.
Reduced GSPT1, IKZF1, and IKZF3 protein levels in a concentration-dependent manner.
Left ZFP91 protein levels unchanged across all tested concentrations.
-
Cell Line:HT-29 colorectal cancer cells
-
Concentration:0.0001, 0.0003, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 10 μM
-
Incubation Time:24 h
-
Result:Degraded MEK1 with a DC50 of 118 nM in a concentration-dependent manner.
Degraded MEK2 with a DC50 of 55 nM in a concentration-dependent manner.
Inhibited phosphorylation of MEK and ERK in a concentration-dependent manner.
-
Cell Line:SK-MEL-28 melanoma cells
-
Concentration:0.0001, 0.0003, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 10 μM
-
Incubation Time:24 h
-
Result:Degraded MEK1 with a DC50 of 94 nM in a concentration-dependent manner.
Degraded MEK2 with a DC50 of 38 nM in a concentration-dependent manner.
Inhibited phosphorylation of MEK and ERK in a concentration-dependent manner.
-
Cell Line:HT-29 colorectal cancer cells
-
Concentration:0.3 μM
-
Incubation Time:0-24 h
-
Result:Induced significant MEK1/2 degradation starting at 4 h.
Reached maximum MEK1/2 degradation within 8-10 h.
Inhibited ERK phosphorylation starting at 8-10 h.
-
Cell Line:HT-29 colorectal cancer cells
-
Concentration:0.3 μM
-
Incubation Time:8 h
-
Result:Blocked MEK1/2 degradation induced by MS910 via pretreatment with PD0325901, MG-132, MLN4924, and pomalidomide.
Restored pMEK and pERK levels via pretreatment with PD0325901, MG-132, MLN4924, and pomalidomide.
-
Cell Line:HT-29 colorectal cancer cells
-
Concentration:0.0001, 0.0003, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 10 μM
-
Incubation Time:24 h
-
Result:Did not significantly reduce GSPT1, IKZF1, or ZFP91 protein levels at concentrations up to 10 μM.
Significantly decreased IKZF3 protein levels at concentrations above 1 μM, with lower potency for IKZF3 degradation compared to MEK1/2.
Chemical Information
-
No. CAS 2756323-28-9
-
Peso molecular 984.75
-
Fòrmula C41H48F3IN6O11
-
SMILES
O=C(C1=CC=C(C(F)=C1NC2=CC=C(C=C2F)I)F)NOCCCNCCOCCOCCOCCOCCOCCNC3=CC=C4C(N(C5C(NC(CC5)=O)=O)C(C4=C3)=O)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)